Navigation Links
VaxyGen Manufacturing Services LLC Announces Exclusive License and Collaborative Agreement with Georgia State University Research Foundation to Commercialize Novel Biological Process Development Patent, Expertise & Know-How
Date:10/19/2011

ATLANTA, Oct. 19, 2011 /PRNewswire/ -- VaxyGen Manufacturing Services LLC ("VaxyGen") announced today the signing of an exclusive license and collaboration agreement with Georgia State University Research Foundation ("GSURF") to provide VaxyGen the exclusive license to a novel patent for producing and purifying proteins in development as biopharmaceutical and vaccine products. In addition, VaxyGen and GSURF established a collaborative agreement whereby VaxyGen will commercialize the expertise and know-how resident in the Georgia State University Biological Process Development and Research Laboratory. Under the terms of the collaborative agreement, Professors George Pierce and Sid Crow will become Scientific/Technical Advisors to VaxyGen and Drs. Trudy Tucker and Shelby Jones will work with VaxyGen in the commercial development of the resident know-how and technology.

Commenting on the license and collaborative agreement, David Dodd, President/CEO, VaxyGen stated, "We have been most impressed with the expertise, know-how, technology and productivity resident within the GSU Biological Process Development and Research Laboratory. One of the greatest identified challenges in the development of life-enhancing biopharmaceutical and vaccine products is establishing consistent, successful optimization, purification and production of the underlying proteins related to development products. The GSU team has demonstrated their novel ability and consistent success in addressing and resolving these very challenging technical issues. We are confident that the biopharmaceutical and vaccine development marketplace will welcome and benefit from the broad commercialization of this technology and overall capability. In the end, patients will most benefit from the contributions resulting from this license and collaboration. We believe that this license and collaborative agreement are an excellent demonstration of improving life through affordable innovation."

Jim Weyhenmeyer, Ph.D., Chairman of GSURF and Vice President for Research and Economic Development at Georgia State University ("GSU"), added, "This agreement between GSURF and VaxyGen is a significant step in demonstrating the high-value translation of research at Georgia State University to improve human life through the successful development of biopharmaceutical and vaccine products. We are proud of the outstanding expertise and knowhow that has been developed at GSU's Biological Process Development and Research Laboratory and, we look forward to the successful contributions of that technology and expertise, ultimately to improve lives throughout the world. VaxyGen is an excellent partner to lead the successful translation of this expertise and know-how into the industry marketplace."

About VaxyGen Manufacturing Services LLC

VaxyGen Manufacturing Services LLC provides custom contract services in support of biological process optimization, scale-up and the development of manufacturing processes relative to biopharmaceutical and vaccine products. The Company is one of the operating businesses within VaxyGen Holdings LLC. VaxyGen Holdings LLC was established to provide vaccine products, assay services and manufacturing services, focused on improving life through affordable innovation.

About Georgia State University Research Foundation

The Georgia State University Research Foundation, Inc. (GSURF) is a Georgia nonprofit corporation created to support the research, technology commercialization and economic development activities of GSU. GSURF works to obtain research support funding through individuals, private organizations and public agencies. Grants awarded to the foundation are provided to the university, where scientists are given needed resources to conduct cutting edge research in a variety of fields, leading to new scientific understanding and technologies.

Contact:
Kathryn D. Gallagher
VaxyGen Manufacturing Services LLC
645 Meeting St.
Suite 2
Charleston, SC 29403
kgallagher@vaxygen.com
843/576-9840


'/>"/>
SOURCE VaxyGen Manufacturing Services LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Access Pharmaceuticals Updates MuGard Website with New Video Featuring Clinical Feedback and Manufacturing Footage
2. FDA Awards NIPTE Potential $35 Million in Grants to Reform Drug Manufacturing Process
3. Pharmaceutical Contract Manufacturing: World Market Outlook 2011-2021
4. Director of Commerce, Rogers Weed, Presided Over Ribbon Cutting Ceremony Celebrating Opening of Expanded Manufacturing Facility at CMC Biologics
5. Global Markets for Contract Pharmaceutical Manufacturing, Research And Packaging: Focus on Emerging Markets
6. Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets
7. Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging: Focus on North America
8. Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging: Focus on Europe
9. Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing
10. CMC Biologics Adds 2,000 Liter Single-Use Bioreactor at its Copenhagen Manufacturing Facility
11. Medical Device Manufacturing Conference Slated for October 19-20, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Dec. 6, 2016 A new study released ... (AIR 340B) projects the 340B Drug Pricing Program will continue ... time it is expected to exceed $23 billion in total ... 340B purchases surpass current Medicare Part B drug reimbursement purchases ... study – based on analysis of data on total drug ...
(Date:12/6/2016)... VANCOUVER , Dec. 6, 2016 /PRNewswire/ - ... announced progress today on its R&D program in ... chronic obstructive pulmonary disease (COPD). In June, 2015 ... analysis tool to identify the targets and potential ... treatment of COPD. Subsequently, with in vitro assays ...
(Date:12/6/2016)... 6, 2016  In response to the tragic reality ... 25 minutes, a respected group of local and national ... a holistic suite of services to help Medicaid-eligible mothers ... his own experience trying to help family and friends ... Lanning launched 180 Health Partners to ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... ... bioelectronic medicine device WellnessPro Plus for consumers and healthcare professionals to manage ... platform by expanding the treatment modalities available in a single device. The ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Fred Rides a Train” allows readers to ... , “Fred Rides a Train” is the creation of published author, Janet Morrison, ... teen years in Michigan. The "Fred, the Dog" series is her first attempt at ...
(Date:12/7/2016)... ... December 07, 2016 , ... "Hacking into my medical ... described him as 'a genius.'" Thus begins "Margaret in Berlin," Book Twelve in the ... by Wyston Books, Inc. These novels narrate the lives of a poor ...
(Date:12/6/2016)... ... , ... According to a November 1 article published on Bustle, ... not drinking enough water, which can cause bad breath (known medically as halitosis). Dr. ... hygiene not only helps reduce the possibility of bad breath, but it can provide ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... the Maine Women’s Magazine inaugural Maine Women’s Expo. Hundreds of women gathered to ... amazing local resource. The expo’s beneficiary this year was Crossroads, a fully-accredited ...
Breaking Medicine News(10 mins):